secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0001493152-23-041881
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Biosciences receives Nasdaq delisting notice for non-compliance with $2.5M equity requirement
--------------------------------------------------------------------------------

- Notified on Nov 13, 2023 of non-compliance with Nasdaq Rule 5550(b)(1) due to stockholders' equity below $2.5M as of Sept 30, 2023.
- Company plans to timely request a hearing before Nasdaq Hearings Panel, staying delisting pending hearing conclusion.
- No assurance the Panel will grant continued listing or that compliance can be evidenced within any extension period.
- Company intends to actively explore options to regain compliance with Nasdaq listing requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315223041881/0001493152-23-041881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315223041881/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer